PET/CT in cancer research: From preclinical to clinical applications (1198 views)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Review,
Impact factor: 4.02, 5-year impact factor: 4.149
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77956139255&partnerID=40&md5=fc9f8842f054a65507ace506d3efbe67
Keywords: Cancer, Pet Ct, Translational Research, Fluorothymidine F 18, 4 (3 Bromoanilino) 6, 7 Dimethoxyquinazoline, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo[2, 3 D]pyrimidine, Bevacizumab, Cetuximab, Cisplatin, Cyclophosphamide, Doxorubicin, Epidermal Growth Factor Receptor Kinase Inhibitor, Erlotinib, Fluorodeoxyglucose F 18, Fluorouracil, Gefitinib, Histone Deacetylase Inhibitor, Irinotecan, Prednisone, Rituximab, Tracer, Trastuzumab, Tumor Marker, Vincristine, Angiogenesis, Apoptosis, Breast Cancer, Cancer Cell, Cancer Diagnosis, Cancer Invasion, Cancer Research, Cell Proliferation, Colon Carcinoma, Computer Assisted Tomography, Drug Mechanism, Fibrosarcoma, Follicular Lymphoma, Gene Targeting, Glioblastoma, Human, Lung Non Small Cell Cancer, Metastasis, Nonhuman, Positron Emission Tomography, Priority Journal, Protein Expression, Review, Squamous Cell Carcinoma, Treatment Response, Animals, Neoplasms, Positron-Emission Tomography, X-Ray Computed, Neoplasms Diagnosis Radiography Radionuclide Imaging, Positron-Emission Tomography Methods, X-Ray Computed Methods, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo [2, 3 D] Pyrimidine, Neoplasms Diagnosis Diagnostic Imaging,
Affiliations:
*** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples 'Federico II', Edificio 10, Via S. Pansini, 5, Naples 80131, Italy
Institute of Biostructures and Bioimages, National Research Council, Naples, Italy
References:
Not available.
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Review,
Impact factor: 4.02, 5-year impact factor: 4.149
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77956139255&partnerID=40&md5=fc9f8842f054a65507ace506d3efbe67
Keywords: Cancer, Pet Ct, Translational Research, Fluorothymidine F 18, 4 (3 Bromoanilino) 6, 7 Dimethoxyquinazoline, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo[2, 3 D]pyrimidine, Bevacizumab, Cetuximab, Cisplatin, Cyclophosphamide, Doxorubicin, Epidermal Growth Factor Receptor Kinase Inhibitor, Erlotinib, Fluorodeoxyglucose F 18, Fluorouracil, Gefitinib, Histone Deacetylase Inhibitor, Irinotecan, Prednisone, Rituximab, Tracer, Trastuzumab, Tumor Marker, Vincristine, Angiogenesis, Apoptosis, Breast Cancer, Cancer Cell, Cancer Diagnosis, Cancer Invasion, Cancer Research, Cell Proliferation, Colon Carcinoma, Computer Assisted Tomography, Drug Mechanism, Fibrosarcoma, Follicular Lymphoma, Gene Targeting, Glioblastoma, Human, Lung Non Small Cell Cancer, Metastasis, Nonhuman, Positron Emission Tomography, Priority Journal, Protein Expression, Review, Squamous Cell Carcinoma, Treatment Response, Animals, Neoplasms, Positron-Emission Tomography, X-Ray Computed, Neoplasms Diagnosis Radiography Radionuclide Imaging, Positron-Emission Tomography Methods, X-Ray Computed Methods, 6 (4 Hydroxyphenyl) 4 (alpha Methylbenzylamino) 7h Pyrrolo [2, 3 D] Pyrimidine, Neoplasms Diagnosis Diagnostic Imaging,
Affiliations:
*** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples 'Federico II', Edificio 10, Via S. Pansini, 5, Naples 80131, Italy
Institute of Biostructures and Bioimages, National Research Council, Naples, Italy
References:
Not available.
PET/CT in cancer research: From preclinical to clinical applications
The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy. Copyright © 2010 John Wiley & Sons, Ltd.
The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy. Copyright © 2010 John Wiley & Sons, Ltd.
PET/CT in cancer research: From preclinical to clinical applications
| ▼ Complementary use of preclinical imaging in minipig model studies |
| ▼ Phenotyping of murine models by preclinical imaging |
PET/CT in cancer research: From preclinical to clinical applications
Other filter: ([btitle,keywords] "Translational Resear ...
Perri F, Ionna F, Muto P, Marzo MD, Caponigro F, Longo F, Vittoria Scarpati GD, Lorenzo GD, Giuliano M, Solla R
* Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy (515 views)
Future Sci Oa (ISSN: 2056-5623linking), 2018 Oct 26; 5(1): FSO347-FSO347.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (1131 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (1142 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (1228 views)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (1139 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
* Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy (515 views)
Future Sci Oa (ISSN: 2056-5623linking), 2018 Oct 26; 5(1): FSO347-FSO347.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (1131 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (1142 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (1228 views)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (1139 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
5 Records (5 excluding Abstracts).
Total impact factor: 18.263 (18.263 excluding Abstracts).
Total 5 year impact factor: 19.512 (19.512 excluding Abstracts).
Total impact factor: 18.263 (18.263 excluding Abstracts).
Total 5 year impact factor: 19.512 (19.512 excluding Abstracts).
1198 views. Last view on Friday 23 May 2025, 16:45:56
ibb.cnr.it
